Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of “Buy” from Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has been given an average recommendation of “Buy” by the eight analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $13.71.

HUMA has been the topic of several recent research reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and issued a $15.00 target price (up previously from $12.00) on shares of Humacyte in a report on Friday, December 20th. Finally, Benchmark restated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th.

Institutional Trading of Humacyte

Hedge funds have recently bought and sold shares of the business. Vontobel Holding Ltd. bought a new stake in Humacyte during the fourth quarter worth $50,000. Petros Family Wealth LLC bought a new stake in Humacyte during the fourth quarter worth $50,000. Syon Capital LLC bought a new stake in Humacyte during the fourth quarter worth $54,000. Brookstone Capital Management bought a new stake in Humacyte during the fourth quarter worth $56,000. Finally, ACT Wealth Management LLC purchased a new stake in Humacyte in the fourth quarter worth $57,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte Stock Performance

Shares of NASDAQ:HUMA opened at $3.06 on Tuesday. The business’s 50 day simple moving average is $4.33 and its two-hundred day simple moving average is $4.92. The firm has a market cap of $385.13 million, a P/E ratio of -2.28 and a beta of 1.30. Humacyte has a 52-week low of $2.81 and a 52-week high of $9.97.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.